Mitchell Fink
Direktor/Vorstandsmitglied bei Midway Pharmaceuticals, Inc.
Profil
Mitchell P.
Fink is the founder of Immunetrics, Inc. (2001).
He is also the founder of Critical Therapeutics, Inc., Logical Therapeutics, Inc. Dr. Fink's current job is Director at Midway Pharmaceuticals, Inc. Dr. Fink's former jobs include Chief Executive Officer at Lycera Corp., Chairman at Inotek Pharmaceuticals Corp.
(2010), and Chairman at the University of Pittsburgh.
Dr. Fink received a doctorate degree from the University of Washington.
Aktive Positionen von Mitchell Fink
Unternehmen | Position | Beginn |
---|---|---|
Midway Pharmaceuticals, Inc.
Midway Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Midway Pharmaceuticals, Inc. develops non-antibiotic therapies. It capitalizes on the finding the molecular weight polymers, taken orally but not systemically absorbed, can inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing. The company was founded by John Alverdy, Eugene Chang and Elaine Petrof in 2005 and is headquartered in Spring House, PA. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Mitchell Fink
Unternehmen | Position | Ende |
---|---|---|
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | Präsident | - |
Immunetrics, Inc.
Immunetrics, Inc. BiotechnologyHealth Technology Immunetrics, Inc. operates as a bio-simulation company. The company was founded by Carson Chow, Timothy R. Billiar, Gilles Clermont, Mitchell P. Fink and Yoram Vodovotz in 2001 and is headquartered in Pittsburgh, PA. | Gründer | - |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Direktor/Vorstandsmitglied | - |
University of Pittsburgh | Vorsitzender | - |
Critical Therapeutics, Inc. | Gründer | - |
Ausbildung von Mitchell Fink
University of Washington | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
Logical Therapeutics, Inc.
Logical Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Logical Therapeutics, Inc. develops products that treat diseases associated with inflammation. It provides a platform of bio-activated prodrugs for the chronic treatment of arthritis. Its bio-activated NSAID prodrugs are chemical entities that are designed to reduce the incidence of GI ulcers and improve GI tolerability in patients who require chronic NSAID treatment. The company was founded by Carolyn E. Green in 2005 and is headquartered in Waltham, MA. | Health Technology |
Critical Therapeutics, Inc. | Health Technology |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
Immunetrics, Inc.
Immunetrics, Inc. BiotechnologyHealth Technology Immunetrics, Inc. operates as a bio-simulation company. The company was founded by Carson Chow, Timothy R. Billiar, Gilles Clermont, Mitchell P. Fink and Yoram Vodovotz in 2001 and is headquartered in Pittsburgh, PA. | Health Technology |
Midway Pharmaceuticals, Inc.
Midway Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Midway Pharmaceuticals, Inc. develops non-antibiotic therapies. It capitalizes on the finding the molecular weight polymers, taken orally but not systemically absorbed, can inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing. The company was founded by John Alverdy, Eugene Chang and Elaine Petrof in 2005 and is headquartered in Spring House, PA. | Health Technology |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | Health Technology |